Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 75,500 |
5 mg | 在庫あり | ¥ 183,500 |
10 mg | 在庫あり | ¥ 250,500 |
25 mg | 在庫あり | ¥ 379,000 |
50 mg | 在庫あり | ¥ 512,000 |
100 mg | 在庫あり | ¥ 672,500 |
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 198,000 |
説明 | AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties. |
In vivo | AZ-1355 consistently decreases serum total cholesterol (TC) in Triton-induced hyperlipidemic mice at a dose of 150 mg/kg. At a lower dose of 50 mg/kg, it significantly lowers serum triglycerides (TG), while a 100 mg/kg dose effectively reduces both serum TC and TG in rats. Additionally, the 100 mg/kg dosage diminishes total liver TC in rats consuming a CE-2 diet, and a 50 mg/kg dose not only reduces liver TC in rats on a high-fat diet but also decreases total hepatic TG in CE-2 fed rats[1]. |
細胞研究 | The lipid-lowering profile in rodents AZ-1355, A New Dibenzoxazepine Derivative |
動物実験 | AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice. AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rats. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high-fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. |
分子量 | 299.32 |
分子式 | C17H17NO4 |
CAS No. | 75451-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (75.17 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AZ-1355 75451-07-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor AZ 1355 AZ1355 Inhibitor inhibitor inhibit